alycante: axi-cel as second-line therapy for transplant-ineligible patients with r/r lbcl
Published 1 year ago • 159 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
2:45
the value of axi-cel as a second-line treatment in r/r lbcl
-
1:21
approval of axi-cel in second-line for r/r lbcl & label update
-
2:18
matched-adjusted comparison of liso-cel versus axi-cel for the second-line treatment of r/r lbcl
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
0:59
matching-adjusted indirect comparison of liso-cel vs axi-cel in the 2l treatment of r/r lbcl
-
3:46
the impact of cytogenetic risk on outcomes of haploidentical transplantation in r/r aml
-
0:38
optimal time for allo-hsct in aml
-
14:43
current research into post-allosct maintenance therapy in aml
-
2:00
utilizing cytokine profiles at baseline to predict cytopenia after treatment with ide-cel
-
1:22
react: elispot assay predicts cmv reactivation in allo-hsct patients
-
3:23
ace axcel for biopharma research labs
-
6:31
how to operate acro's clinmax cytokine elisa kits
-
2:11
synergistic activity of alnuctamab and celmods in multiple myeloma preclinical models
-
2:42
the impact of jak2 allele burden and cytopenia on mf outcome in the era of ruxolitinib
-
2:25
novel ai model for personalized risk stratification & treatment in newly diagnosed multiple myeloma
-
0:45
altogen biosystems neuro-2a transfection reagent
-
58:13
optimising transplant outcome in adults allografted for aml
-
0:45
altogen biosystems ar42j transfection kit
-
1:52
aml: the cytogenetic risk score